1-(quinoxalin-6-ylcarbonyl)piperidine (CX516)

10/01/2001 - "These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia."
11/01/2009 - "The current study evaluated the effect of ampakine CX516 in reversing deficits in executive functioning as represented in two animal models of schizophrenia and assessed by a rodent analog of the intradimensional-extradimensional (ID-ED) attentional set-shifting task. "
02/01/2008 - "A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia."
02/01/2008 - "CX516 is the first Ampakine to be studied for cognitive enhancement in schizophrenia. "
10/01/2002 - "Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series."

10/01/2006 - "A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). "
10/01/2006 - "Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial."

01/01/2006 - "Randomised trial data are available for antihypertensive agents (calcium channel blockers, angiotensin-converting enzyme inhibitors), pravastatin, simvastatin, conjugated oestrogen, raloxifene, rofecoxib, CX516 (AMPA agonist) and cholinesterase inhibitors regarding efficacy for Alzheimer's disease prevention. "

08/01/2002 - "The study medication for the double-blind, placebo-controlled trial, the AMPAKINE CX516, represents a novel pharmacological approach to the treatment of memory disorders. "

10/13/2009 - "Finally, one study on patients with an additional diagnosis of autism assessed ampakine compound CX516 and found no significant differences between treatment and placebo. "